insights_auto
„Outlook“: 92.9 proc. tikisi, kad kaina augs·0.0 proc. tikisi, kad kaina kris
Eiti į analizęchevron_right
LGND:NASDAQ
Ligand Pharmaceuticals Inc
322,75 USD
arrow_upward
+1,71%(+5,42) 1 D.
324,00 USD
arrow_upward
+0,39% (+1,25)bedtimeUždarius biržą
Uždaryta: 10-30, 16:00:01 GMT−4 · USD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „LGND“ įžvalgos...
Atidaryti
319,22 USD
Aukšta
324,90 USD
Žema
314,50 USD
Rinkos kapitalizacija
6,43 mlrd.
Vid. kiekis
258,62 tūkst.
Apimtis
344,31 tūkst.
P/E santykis
34,33
52 sav. aukšta
326,63 USD
52 sav. žema
175,89 USD
Pajamos iš vienos akcijos
9,40 USD
Beta
1,06
Neapmokėtos akcijos
19,94 mln.
Darbuotojų skaičius
47
Atidaryti
319,22 USD
Aukšta
324,90 USD
Žema
314,50 USD
Rinkos kapitalizacija
6,43 mlrd.
Vid. kiekis
258,62 tūkst.
Apimtis
344,31 tūkst.
P/E santykis
34,33
52 sav. aukšta
326,63 USD
52 sav. žema
175,89 USD
Pajamos iš vienos akcijos
9,40 USD
Beta
1,06
Neapmokėtos akcijos
19,94 mln.
Darbuotojų skaičius
47
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Investing.com Nigeria
·
prieš 9 valandas
Form 144 LIGAND PHARMACEUTICALS INC For: 31 October By Investing.com
Yahoo Finance
·
prieš 1 dieną
Ligand Pharmaceuticals Incorporated Q3 2026 Earnings Call Summary
GuruFocus
·
prieš 1 dieną
Ligand Pharmaceuticals (LGND) Reports 51% Q3 Royalty Revenue Sur
Investing.com
·
prieš 1 dieną
Stifel raises Ligand Pharma stock price target on strong earnings
Profilis
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Apie „Ligand Pharmaceuticals Inc“
Generalinis direktorius-
Darbuotojai47
Įkurtarugs. 1987
Pagrindinė būstinėJupiter, Florida, Jungtinės Valstijos
Sektorius-
Svetainėligand.com